Advancing Rare Disease Therapies Across the Finish Line
Drug development is a marathon, often taking years to complete. This is especially true in rare disease, where the development path is rarely linear.
Unfortunately, this process sometimes requires a relay, as corporate strategy shifts result in promising programs getting deprioritized mid-way through development.
Oak Hill Bio was founded to take the baton where others left off—acquiring and developing outstanding deprioritized late-stage rare disease drugs and bringing them across the finish line.
If you're looking for information about Oak Hill Bio, OHB Pediatrics Ltd, or rugonersen please visit www.oakhillbio.com
Advancing
Breakthroughs
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been deprioritized by big pharma. Our pipeline includes two late-stage therapeutic candidates: rugonersen (OHB-724), an antisense oligonucleotide (ASO) for Angelman syndrome, and mecasermin rinfabate (OHB-607), recombinant human IGF-1/IGFBP-3, for complications of extremely premature birth.
In The Press
